Praluent Safety Study Requirements: A Backdoor To Ensuring Outcomes Trial Completion?
Executive Summary
Agency requires three post-marketing studies under the FDA Amendments Act's drug safety authorities; Sanofi says some of the requirements will be answered by data collected in the ongoing ODYSSEY OUTCOMES trial.
You may also be interested in...
Gilead, US FDA Ponder Innovative Designs For Descovy HIV Prevention Study In Women
Advisory committee sent a clear message that pre-exposure prophylaxis studies are needed in cisgender women, but what those studies might look like, and whether the agency can exercise its statutory authorities to ensure they are conducted, is less clear.
Rare Diseases: CBER Looks To ‘Lean Into’ Accelerated Approval, Align More With CDER
US FDA biologics center officials spoke about their efforts to increase collaboration and harmonization with the drugs center, and to internally involve more review disciplines in evaluating biomarker evidence, during a Reagan-Udall Foundation meeting that weighed potential use of accelerated approval for neuronopathic mucopolysaccharidoses disorders.
RWE: Non-Interventional Studies Must Be Able To Distinguish A True Treatment Effect, US FDA Says
Agency describes a host of issues sponsors should consider and address before pursuing observational or case-control studies to support regulatory decision-making on drug efficacy or safety; new draft guidance was issued under the FDA’s Real-World Evidence program.